{"id":1491,"date":"2022-11-21T09:13:57","date_gmt":"2022-11-21T15:13:57","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=1491"},"modified":"2022-12-13T11:21:16","modified_gmt":"2022-12-13T17:21:16","slug":"vaccines-and-drugs-in-the-pipeline-for-rsv","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2022\/11\/21\/vaccines-and-drugs-in-the-pipeline-for-rsv\/","title":{"rendered":"Vaccines and drugs in the pipeline for RSV"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p>(<a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/vaccines-drugs-pipeline-rsv-2022-11-18\/\">Reuters<\/a>) There are no approved vaccines and only one drug in the United States for respiratory syncytial virus (RSV), a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Sanofi and AstraZeneca drug nirsevimab recently became the second to get Europe&#8217;s approval to prevent RSV infections in infants, after Swedish drugmaker Orphan Biovitrum&#8217;s Synagis. Nirsevimab does not have U.S. approval yet.<\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>(Reuters) There are no approved vaccines and only one drug in the United States for respiratory syncytial virus (RSV), a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Sanofi and AstraZeneca drug nirsevimab recently became the second to get Europe&#8217;s approval to prevent RSV infections [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[47],"tags":[],"class_list":["post-1491","post","type-post","status-publish","format-standard","hentry","category-rsv-therapies"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=1491"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1491\/revisions"}],"predecessor-version":[{"id":1492,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1491\/revisions\/1492"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=1491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=1491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=1491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}